EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of RelB-targeting small-molecule inhibitors of non-canonical NF-κB signaling with antitumor efficacy

Cuifeng Li, Shuqi Wei, Donglin Sun, Zhuo Yang, Qi Wang, Han Lin, Haohao Zhang, Yiming Hu, Dandan Liu, Deji Ye, Yu Tao, Zhanjie Liu und 12 weitere

Molecular Therapy · 2025-04 · 33 (4) · 1519-1534

DOI: 10.1016/j.ymthe.2025.01.048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025-04. Verfasst von Cuifeng Li und 23 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital, The Sixth Affiliated Hospital, Affiliated Cancer Hospital and Institute, GMU-GIBH Joint School of Life Sciences of Gu…. Hauptthemen laut MEDLINE: Transcription Factor RelB, Signal Transduction, NF-kappa B, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysfunction of the non-canonical nuclear factor κB (NF-κB) signaling pathway has been causally associated with numbers of cancers and autoimmune diseases. However, specific inhibitors for this signaling pathway remain to be developed. Here, we showed that structure-based cell-based screening yielded a potent and specific small molecule targeting RelB to inhibit the non-canonical NF-κB signaling pathway, while it had no inhibitory effect on the canonical NF-κB signaling pathway. Mechanistically, the inhibitor directly interacted with RelB protein and disrupted RelB binding to its target DNA, thus repressing RelB transactivity on target genes. Through blocking oncogenic activity of the non-canonical NF-κB signaling pathway in colorectal cancer or B lymphoma, the inhibitor efficiently exerted a potent antitumor effect in vitro and in vivo. Thus, our study provided a new RelB-targeting inhibitor that inhibited the non-canonical NF-κB signaling pathway and facilitated precise therapeutic applications in cancers and possibly other diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcription Factor RelBSignal TransductionNF-kappa BAntineoplastic AgentsSmall Molecule LibrariesHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysProtein Binding

Stichwörter der Autor:innen

B lymphomaRS47RelBcolorectal cancerinhibitornon-canonical NF-κBtumorigenesis

Substanzen

Transcription Factor RelBNF-kappa BAntineoplastic AgentsRELB protein, humanSmall Molecule Libraries

Autor:innen und Institutionen

  • The Second Affiliated Hospital, The Sixth Affiliated Hospital, Affiliated Cancer Hospital and Institute, GMU-GIBH Joint School of Life Sciences of Guangzhou Medical University, The Guangdong-Hong Kong-Macau Joint Labora…
  • CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 201203, China.
  • CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
  • CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China; Shanghai Frontiers Sci…
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200032, China.
  • CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 201203, China. Electronic…

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Li, C., Wei, S., Sun, D., Yang, Z., Wang, Q., Lin, H., Zhang, H., Hu, Y., Liu, D., Ye, D., Tao, Y., Liu, Z., Xu, Z., Li, B., Li, L., Zhang, J., Chen, X., Xie, N., Shi, Y., …, & Zhang, X. (2025). Development of RelB-targeting small-molecule inhibitors of non-canonical NF-κB signaling with antitumor efficacy. Molecular Therapy, 33(4), 1519-1534. https://doi.org/10.1016/j.ymthe.2025.01.048

Vancouver

Li C, Wei S, Sun D, Yang Z, Wang Q, Lin H, et al. Development of RelB-targeting small-molecule inhibitors of non-canonical NF-κB signaling with antitumor efficacy. Molecular Therapy. 2025;33(4):1519-1534. doi:10.1016/j.ymthe.2025.01.048

BibTeX
@article{Li2025,
  author = {Li, Cuifeng and Wei, Shuqi and Sun, Donglin and Yang, Zhuo and Wang, Qi and Lin, Han and Zhang, Haohao and Hu, Yiming and Liu, Dandan and Ye, Deji and Tao, Yu and Liu, Zhanjie and Xu, Zhijian and Li, Bo and Li, Lingling and Zhang, Jie and Chen, Xi and Xie, Ningxia and Shi, Yufang and Liu, Sanhong and Liu, Yongzhong and Jiang, Yuhang and Zhu, Weiliang and Zhang, Xiaoren},
  title = {Development of RelB-targeting small-molecule inhibitors of non-canonical NF-κB signaling with antitumor efficacy},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {4},
  pages = {1519--1534},
  doi = {10.1016/j.ymthe.2025.01.048}
}
Kostenlos starten →